COMMUNIQUÉS West-GlobeNewswire
-
NovaBridge Biosciences to Participate in Upcoming Investor Conferences
09/11/2026 -
GT Biopharma Oral Presentation at the SITC 2026 Annual Meeting
09/11/2026 -
Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
09/11/2026 -
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
09/11/2026 -
Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights
09/11/2026 -
Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing
09/11/2026 -
Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
09/11/2026 -
Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
09/11/2026 -
Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year
09/11/2026 -
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
09/11/2026 -
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference
09/11/2026 -
Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
09/11/2026 -
BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC
09/11/2026 -
J-Star Holding Co., Ltd. Highlights U.S. Operational Progress with Delegation Visit from Global Tier 1 Carbon Fiber Manufacturer
09/11/2026 -
Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights
09/11/2026 -
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
09/11/2026 -
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2026
09/11/2026 -
Transactions in connection with and conclusion of share buy-back program
09/11/2026 -
iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells
09/11/2026
Pages